JP2021512922A - ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 - Google Patents

ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 Download PDF

Info

Publication number
JP2021512922A
JP2021512922A JP2020542875A JP2020542875A JP2021512922A JP 2021512922 A JP2021512922 A JP 2021512922A JP 2020542875 A JP2020542875 A JP 2020542875A JP 2020542875 A JP2020542875 A JP 2020542875A JP 2021512922 A JP2021512922 A JP 2021512922A
Authority
JP
Japan
Prior art keywords
hydrogen
methyl
compound according
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542875A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019155468A5 (https=
JP2021512922A5 (https=
Inventor
スニル‐アルカライ イリト
スニル‐アルカライ イリト
ヴァッカ ジョセフ
ヴァッカ ジョセフ
ベン‐ネリアフ イノン
ベン‐ネリアフ イノン
Original Assignee
イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー.
イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー., イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー. filed Critical イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー.
Publication of JP2021512922A publication Critical patent/JP2021512922A/ja
Publication of JPWO2019155468A5 publication Critical patent/JPWO2019155468A5/ja
Publication of JP2021512922A5 publication Critical patent/JP2021512922A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020542875A 2018-02-08 2019-02-07 ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 Pending JP2021512922A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627908P 2018-02-08 2018-02-08
US201862627921P 2018-02-08 2018-02-08
US62/627,908 2018-02-08
US62/627,921 2018-02-08
PCT/IL2019/050151 WO2019155468A1 (en) 2018-02-08 2019-02-07 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2021512922A true JP2021512922A (ja) 2021-05-20
JPWO2019155468A5 JPWO2019155468A5 (https=) 2022-02-17
JP2021512922A5 JP2021512922A5 (https=) 2022-02-17

Family

ID=65635772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542875A Pending JP2021512922A (ja) 2018-02-08 2019-02-07 ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用

Country Status (11)

Country Link
US (2) US20200383984A1 (https=)
EP (1) EP3749666A1 (https=)
JP (1) JP2021512922A (https=)
KR (1) KR20200130287A (https=)
CN (1) CN111971280A (https=)
AU (1) AU2019219678A1 (https=)
BR (1) BR112020016064A2 (https=)
CA (1) CA3090063A1 (https=)
IL (1) IL276290A (https=)
MX (1) MX2020008375A (https=)
WO (1) WO2019155468A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520126A (ja) * 2022-06-01 2025-07-01 シムライズ アーゲー シクロプロピル構造を有するフレグランス

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384172B (es) 2015-08-04 2025-03-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de pirazol pirimidina y sus usos.
IL288547B2 (en) * 2019-06-03 2025-10-01 Biotheryx Inc Non-hygroscopic crystalline pyrazole compound salts, pharmaceutical preparations thereof and use thereof
US20230047732A1 (en) * 2020-01-13 2023-02-16 Biotheryx, Inc. Pyrazolylpyrimidines and use thereof
WO2022204220A1 (en) * 2021-03-24 2022-09-29 Biotheryx, Inc. Pyrazolylpyrimidines for treating malignant solid tumor
US11752151B2 (en) * 2021-07-12 2023-09-12 Buddhist Tzu Chi Medical Foundation Method for enhancing hair growth
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2017021969A1 (en) * 2015-08-04 2017-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole pyrimidine derivative and uses thereof
JP2018063740A (ja) * 2016-10-13 2018-04-19 パナソニックIpマネジメント株式会社 光ディスク装置、光ディスク読み出し方法
JP7142646B2 (ja) * 2017-02-01 2022-09-27 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー. がんを治療するためのck1及び/又はirak1インヒビターとしてのn1-(4-(5-(シクロプロピルメチル)-1-メチル-1h-ピラゾール-4-イル)ピリジン-2-イル)シクロヘキサン-1,4-ジアミン誘導体及び関連化合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637809A (en) 1968-07-05 1972-01-25 Ciba Geigy Corp Antioxidants
US3698123A (en) 1971-12-06 1972-10-17 Carl R Heldt Structural toys
US3917899A (en) 1972-08-04 1975-11-04 Michael J Oliver Plate for adjustably mounting electrical receptacle
US3846770A (en) 1973-07-11 1974-11-05 Us Navy Serial access memory using magnetic domains in thin film strips
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2839461C2 (de) 1978-09-11 1987-01-15 Bergwerksverband Gmbh, 4300 Essen Formmassen aus thermoplastischen Kunststoffen und Rückständen der Kohlehydrierung
US4328246A (en) 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US5762756A (en) 1994-11-21 1998-06-09 The Black Clawson Company Methods and apparatus for pulping and deinking
US6069696A (en) 1995-06-08 2000-05-30 Psc Scanning, Inc. Object recognition system and method
US6576139B1 (en) 1996-07-30 2003-06-10 Kenneth C. Hou Process for purifying photoresist composition employing a filter sheet
DE19630939C1 (de) 1996-07-31 1997-12-11 Siemens Ag Kontaktfeder
KR100218318B1 (ko) 1996-10-01 1999-09-01 문정환 주파수 변환장치
US7274662B1 (en) 1998-08-04 2007-09-25 At&T Corp. Method for performing segmented resource reservation
US6062668A (en) 1996-12-12 2000-05-16 Hitachi Koki Imaging Solutions, Inc. Drop detector for ink jet apparatus
US6364667B1 (en) 1997-03-14 2002-04-02 Relational Technologies Llp Techniques for mastering a body of knowledge by writing questions about the body of knowledge
US6073643A (en) 1998-09-14 2000-06-13 Patent Category Corp. Adjustable collapsible panels
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
DE20019821U1 (de) 1999-12-09 2001-06-07 BRAND GMBH + CO KG, 97877 Wertheim Dosiereinrichtung für Flüssigkeiten
JP2003520658A (ja) 2000-01-27 2003-07-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 脊柱の幾何学的データを抽出する方法及びシステム
AU782084B2 (en) 2000-08-15 2005-06-30 Baker Hughes Incorporated Self lubricating swage
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
MXPA03002200A (es) 2000-09-13 2007-10-02 Interdigital Tech Corp Intercalador de modem fdd de tercera generacion.
WO2002028911A2 (en) 2000-10-02 2002-04-11 The University Of Akron Synthesis and characterization of nanocomposites by emulsion polymerization
US7113943B2 (en) 2000-12-06 2006-09-26 Content Analyst Company, Llc Method for document comparison and selection
US7120761B2 (en) 2000-12-20 2006-10-10 Fujitsu Limited Multi-port memory based on DRAM core
JP4007767B2 (ja) 2001-01-18 2007-11-14 日本碍子株式会社 圧電/電歪デバイスおよびその製造方法
US6709874B2 (en) 2001-01-24 2004-03-23 Infineon Technologies Ag Method of manufacturing a metal cap layer for preventing damascene conductive lines from oxidation
US6980946B2 (en) 2001-03-15 2005-12-27 Microsoft Corporation Method for hybrid processing of software instructions of an emulated computer system
WO2002077657A1 (en) 2001-03-22 2002-10-03 Fujitsu Limited Magnetoresistive spin-valve sensor and magnetic storage apparatus
JP4124607B2 (ja) 2001-04-06 2008-07-23 ヤマウチ株式会社 ピンチローラおよびピンチローラ装置
US6840774B2 (en) 2001-05-07 2005-01-11 Jack W. Fretwell, Jr. System to teach, measure and rate learner knowledge of basic mathematics facts
US6798220B1 (en) 2001-06-27 2004-09-28 Timothy H. Flanigan Moisture/mold detector
WO2003004492A1 (en) * 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US6891474B1 (en) 2001-08-01 2005-05-10 Tagsense, Inc. Electromagnetic identification label for anti-counterfeiting, authentication, and tamper-protection
US7345559B2 (en) 2001-09-13 2008-03-18 General Electric Company High field open MRI magnet isolation system and method
US6965468B2 (en) 2003-07-03 2005-11-15 Reflectivity, Inc Micromirror array having reduced gap between adjacent micromirrors of the micromirror array
US7039976B2 (en) 2002-04-09 2006-05-09 Maytag Corporation Braking control system for a washing machine
US6739477B1 (en) 2002-04-12 2004-05-25 Floro Pascual Golf ball dispenser
US7048737B2 (en) 2002-06-11 2006-05-23 Bioplate, Inc. Cranial bone flap fixation system and method
WO2004001741A1 (en) 2002-06-21 2003-12-31 Seagate Technology Llc Fluid dynamic bearing asymmetry pressure feedback
CA2496197A1 (en) * 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
DE10240053A1 (de) 2002-08-30 2004-03-11 Robert Bosch Gmbh Brückenzünder-Zündelement
US6739108B2 (en) 2002-09-30 2004-05-25 Allpax Products, Inc. Fragile container handling system for retort/sterilization processes
JP2004158619A (ja) 2002-11-06 2004-06-03 Matsushita Electric Ind Co Ltd 電子デバイスおよびその製造方法
US6712069B1 (en) 2002-11-20 2004-03-30 William L. Spangler Solar energy collection and storage system
US7139876B2 (en) 2003-01-16 2006-11-21 Ip-First, Llc Microprocessor and apparatus for performing fast speculative pop operation from a stack memory cache
ITBO20030105A1 (it) 2003-02-28 2004-09-01 Fasco Spa Pistola pneumatica per elementi di fissaggio.
CN100425492C (zh) 2003-03-19 2008-10-15 日本精工株式会社 电动转向装置以及其中使用的树脂齿轮
US7248373B2 (en) 2003-03-21 2007-07-24 Durr Systems, Inc Workpiece configuration detection system and method
US6867376B2 (en) 2003-04-17 2005-03-15 Bellsouth Intellectual Property Corporation Glow rods with externally mountable anchoring members and related methods
US7069377B2 (en) 2003-05-08 2006-06-27 Micron Technology, Inc. Scratch control memory array in a flash memory device
FR2854693B1 (fr) 2003-05-09 2005-07-01 Siemens Vdo Automotive Procede de determination de l'energie d'un signal de cliquetis pour moteur a combustion interne
EP1658083B1 (en) 2003-06-19 2007-08-08 BODOR, Nicholas S. Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
US6993866B1 (en) 2003-06-25 2006-02-07 James Strange Fishing bait rig attachment apparatus with rotating rattle
US6922367B2 (en) 2003-07-09 2005-07-26 Micron Technology, Inc. Data strobe synchronization circuit and method for double data rate, multi-bit writes
JP4183181B2 (ja) 2003-08-07 2008-11-19 株式会社小松製作所 異物除去装置
DE102004027446B4 (de) 2004-06-04 2007-08-23 Jungheinrich Aktiengesellschaft Vorrichtung zur Unterstützung des Ein- und Ausstapelns bei einem Stapler
US7197360B1 (en) 2005-01-12 2007-03-27 Pacesetter, Inc. Methods and systems for using an inductor to increase capacitor reformation efficiency in an implantable cardiac device (ICD)
US7377471B1 (en) 2005-06-06 2008-05-27 Compton Harry L Method and system for opening and securing a railroad frog
US7271369B2 (en) 2005-08-26 2007-09-18 Aem, Inc. Multilayer positive temperature coefficient device and method of making the same
JP4666514B2 (ja) 2006-07-20 2011-04-06 リンテック株式会社 シート剥離装置及び剥離方法
US7799600B2 (en) 2007-05-31 2010-09-21 Chien-Min Sung Doped diamond LED devices and associated methods
US7689648B2 (en) 2007-06-27 2010-03-30 Microsoft Corporation Dynamic peer network extension bridge
PE20121066A1 (es) * 2009-06-19 2012-09-13 Abbvie Inc Derivados de diazahomoadamantano y metodos para usarlos
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
HK1246273B (en) * 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
HK1245247A1 (zh) * 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
JP2016193861A (ja) * 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
WO2017021970A1 (en) 2015-08-06 2017-02-09 Tower-Sec Ltd Means and methods for regulating can communication
CN109748915B (zh) * 2015-12-09 2021-03-26 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2017021969A1 (en) * 2015-08-04 2017-02-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole pyrimidine derivative and uses thereof
JP2018063740A (ja) * 2016-10-13 2018-04-19 パナソニックIpマネジメント株式会社 光ディスク装置、光ディスク読み出し方法
JP7142646B2 (ja) * 2017-02-01 2022-09-27 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー. がんを治療するためのck1及び/又はirak1インヒビターとしてのn1-(4-(5-(シクロプロピルメチル)-1-メチル-1h-ピラゾール-4-イル)ピリジン-2-イル)シクロヘキサン-1,4-ジアミン誘導体及び関連化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. BIOL., vol. 11, JPN6023002093, 2016, pages 518 - 529, ISSN: 0005138672 *
ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 3, JPN5021006279, 2018, pages 210 - 214, ISSN: 0005138674 *
REGISTRY(STN)[ONLINE], JPN7023000209, 28 August 2018 (2018-08-28), ISSN: 0005138675 *
REGISTRY(STN)[ONLINE], JPN7023000210, 16 September 2009 (2009-09-16), ISSN: 0005138673 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520126A (ja) * 2022-06-01 2025-07-01 シムライズ アーゲー シクロプロピル構造を有するフレグランス

Also Published As

Publication number Publication date
MX2020008375A (es) 2020-09-25
US12138265B2 (en) 2024-11-12
IL276290A (en) 2020-09-30
CA3090063A1 (en) 2019-08-15
US20230233562A1 (en) 2023-07-27
BR112020016064A2 (pt) 2020-12-08
EP3749666A1 (en) 2020-12-16
WO2019155468A1 (en) 2019-08-15
US20200383984A1 (en) 2020-12-10
CN111971280A (zh) 2020-11-20
AU2019219678A1 (en) 2020-08-27
KR20200130287A (ko) 2020-11-18

Similar Documents

Publication Publication Date Title
US12138265B2 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
KR100816945B1 (ko) 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염
TWI807150B (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
JP6042406B2 (ja) (α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ)ピリミジニル及び1,3,5−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
AU2021250904B2 (en) Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
CN103038216A (zh) 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
JP2021121633A (ja) 1−メチル−d−トリプトファンの塩及びプロドラッグ
CN110996959A (zh) 联合疗法
JP2023182589A (ja) フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
WO2011100769A2 (en) Kinase modulators for the treatment of cancer
JP2014509648A (ja) (α−置換シクロアルキルアミノ及びヘテロシクリルアミノ)ピリミジニル及び1,3,5−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
CA3218813A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
TWI703133B (zh) 3,5-二胺基吡唑激酶抑制劑
TW201414721A (zh) 同位素濃化之芳磺醯胺ccr3拮抗劑
JP2025514839A (ja) Cdk阻害剤、医薬組成物及びその治療応用
KR20160061322A (ko) 3,5-디아미노피라졸 키나아제 억제제의 약제학적으로 허용가능한 염
TW201929847A (zh) 包含二羧酸之醫藥組合物及其治療應用
JP2025541836A (ja) ホスホロアミダートモノサッカライド、医薬組成物、並びに診断的及び治療的応用
HK40128737A (zh) 磷醯胺酯单糖、药物组合物及诊断和治疗应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829